Actively Recruiting
Vasoactive Drugs in Intensive Care Unit
Led by University of Chicago · Updated on 2026-01-13
836
Participants Needed
1
Research Sites
654 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.
CONDITIONS
Official Title
Vasoactive Drugs in Intensive Care Unit
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than or equal to 18 years old
- Need for vasoactive drugs via a central venous catheter to treat shock defined by low blood pressure despite receiving at least 1000 mL of crystalloid or 500 mL of colloid fluids unless elevated pressures and signs of poor tissue blood flow are present
You will not qualify if you...
- Cardiopulmonary arrest
- Pregnancy
- Severe right heart failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
J
John P Kress, MD
CONTACT
A
Anne Pohlman
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here